Life Science Investing Forte Biosciences, Inc. Announces Third Quarter 2025 Results and Provides Update
Life Science Investing Forte Biosciences, Inc. Announces Presentation of FB102 Celiac Disease Trial at Tampere Celiac Disease Symposium